Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Which outcomes are most important to measure in patients with COVID-19 and how and when should these be measured? Development of an international standard set of outcomes measures for clinical use in patients with COVID-19: a report of the International Consortium for Health Outcomes Measurement (ICHOM) COVID-19 Working Group.
Seligman WH, Fialho L, Sillett N, Nielsen C, Baloch FM, Collis P, Demedts IKM, Fleck MP, Floriani MA, Gabriel LEK, Gagnier JJ, Keetharuth A, Londral A, Ludwig IIL, Lumbreras C, Moscoso Daza A, Muhammad N, Nader Bastos GA, Owen CW, Powers JH, Russell AM, Smith MK, Wang TY, Wong EK, Woodhouse DC, Zimlichman E, Brinkman K. Seligman WH, et al. Among authors: collis p. BMJ Open. 2021 Nov 15;11(11):e051065. doi: 10.1136/bmjopen-2021-051065. BMJ Open. 2021. PMID: 34782342 Free PMC article.
Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research: The PRO Ethics Guidelines.
Cruz Rivera S, Aiyegbusi OL, Ives J, Draper H, Mercieca-Bebber R, Ells C, Hunn A, Scott JA, Fernandez CV, Dickens AP, Anderson N, Bhatnagar V, Bottomley A, Campbell L, Collett C, Collis P, Craig K, Davies H, Golub R, Gosden L, Gnanasakthy A, Haf Davies E, von Hildebrand M, Lord JM, Mahendraratnam N, Miyaji T, Morel T, Monteiro J, Zwisler AO, Peipert JD, Roydhouse J, Stover AM, Wilson R, Yap C, Calvert MJ. Cruz Rivera S, et al. Among authors: collis p. JAMA. 2022 May 17;327(19):1910-1919. doi: 10.1001/jama.2022.6421. JAMA. 2022. PMID: 35579638
Patient-reported outcomes in the regulatory approval of medical devices.
Cruz Rivera S, Dickens AP, Aiyegbusi OL, Flint R, Fleetcroft C, McPherson D, Collis P, Calvert MJ. Cruz Rivera S, et al. Among authors: collis p. Nat Med. 2021 Dec;27(12):2067-2068. doi: 10.1038/s41591-021-01546-9. Nat Med. 2021. PMID: 34785789 No abstract available.
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
Riedl MA, Aygören-Pürsün E, Baker J, Farkas H, Anderson J, Bernstein JA, Bouillet L, Busse P, Manning M, Magerl M, Gompels M, Huissoon AP, Longhurst H, Lumry W, Ritchie B, Shapiro R, Soteres D, Banerji A, Cancian M, Johnston DT, Craig TJ, Launay D, Li HH, Liebhaber M, Nickel T, Offenberger J, Rae W, Schrijvers R, Triggiani M, Wedner HJ, Dobo S, Cornpropst M, Clemons D, Fang L, Collis P, Sheridan WP, Maurer M. Riedl MA, et al. Among authors: collis p. Allergy. 2018 Sep;73(9):1871-1880. doi: 10.1111/all.13466. Epub 2018 Jun 17. Allergy. 2018. PMID: 29688579 Free PMC article. Clinical Trial.
Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat.
Aygören-Pürsün E, Magerl M, Graff J, Martinez-Saguer I, Kreuz W, Longhurst H, Nasr I, Bas M, Straßen U, Fang L, Cornpropst M, Dobo S, Collis P, Sheridan WP, Maurer M. Aygören-Pürsün E, et al. Among authors: collis p. J Allergy Clin Immunol. 2016 Sep;138(3):934-936.e5. doi: 10.1016/j.jaci.2016.03.043. Epub 2016 May 11. J Allergy Clin Immunol. 2016. PMID: 27302552 Clinical Trial. No abstract available.
66 results